Even then, sufferers received’t get the therapies if insurers and governments balk at paying. It’s an actual danger. As an example, a unique gene remedy for beta-thalassemia, developed by Bluebird Bio, was pulled out of the European market after governments there refused to pay the $1.8 million worth.
CRISPR 2.0
The primary technology of CRISPR therapies are additionally restricted in one other approach. Most use the device to break DNA, basically shutting off genes—a course of famously described as “
